Risedronic acid
- Generic Name
- Risedronic acid
- Brand Names
- Actonel, Atelvia
- Drug Type
- Small Molecule
- Chemical Formula
- C7H11NO7P2
- CAS Number
- 105462-24-6
- Unique Ingredient Identifier
- KM2Z91756Z
- Background
Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.
- Associated Conditions
- Hypercalcemia of Malignancy, Osteoporosis, Paget’s Disease
- Associated Therapies
- -
Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-11-21
- Lead Sponsor
- Toronto Rehabilitation Institute
- Target Recruit Count
- 38
- Registration Number
- NCT00150696
- Locations
- 🇨🇦
Hamilton Health Sciences, Chedoke Site, Hamilton, Ontario, Canada
🇨🇦Toronto Rehab, Lyndhurst Centre, Toronto, Ontario, Canada
Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Toronto Rehabilitation Institute
- Target Recruit Count
- 46
- Registration Number
- NCT00138866
- Locations
- 🇨🇦
Toronto Rehab, Lyndhurst Centre, Toronto, Ontario, Canada
OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women
- Conditions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 290
- Registration Number
- NCT00130403
- Locations
- 🇦🇺
sanofi-aventis, Australia, Cove, New South Wales, Australia
🇨🇦sanofi-aventis, Canada, Laval, Quebec, Canada
🇧🇪sanofi-aventis, Belgium, Diegem, Belgium
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT00103740
- Locations
- 🇬🇧
Novartis Investigative site, Oxford, United Kingdom
🇬🇧Novartis Investigative Site, London, United Kingdom
Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
- First Posted Date
- 2004-05-06
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 237
- Registration Number
- NCT00082277
- Locations
- 🇬🇧
Research Site, Luton, United Kingdom
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 216
- Registration Number
- NCT00054418
- Locations
- 🇺🇸
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 71
- Registration Number
- NCT00043069
- Locations
- 🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Perry Memorial Hospital, Princeton, Illinois, United States
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
- First Posted Date
- 2003-01-15
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 172
- Registration Number
- NCT00051636
- Locations
- 🇬🇧
Novartis Investigative Site, Vale of Glamorgan, United Kingdom
🇬🇧Novartis investigative site, Pernarth, United Kingdom
🇬🇧Novartis Investigative site, Penarth, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.